BR112023019030A2 - Derivados de fósforo como inibidores de sos1 - Google Patents

Derivados de fósforo como inibidores de sos1

Info

Publication number
BR112023019030A2
BR112023019030A2 BR112023019030A BR112023019030A BR112023019030A2 BR 112023019030 A2 BR112023019030 A2 BR 112023019030A2 BR 112023019030 A BR112023019030 A BR 112023019030A BR 112023019030 A BR112023019030 A BR 112023019030A BR 112023019030 A2 BR112023019030 A2 BR 112023019030A2
Authority
BR
Brazil
Prior art keywords
compounds
phosphorus derivatives
sos1
preparing
inhibitors
Prior art date
Application number
BR112023019030A
Other languages
English (en)
Inventor
Marinov Kamburov Atanas
Benjamin Bader
Philipp Hethey Christoph
Felix Pape
Gerhard Siemeister
Jens SCHRÖDER
Xavier G Mortier Jeremie
Katrin Nowak-Reppel
Keith Graham
Matthias Arlt
Michael Erkelenz
Roman Hillig
Steffen Gressies
Timo Stellfeld
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR112023019030A2 publication Critical patent/BR112023019030A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados de fósforo como inibidores de sos1. a presente invenção refere-se a derivados de fósforo de fórmula geral (i), em que r1, r2, r3, r4, r5, r6, x1, x2, x3, x4 e y são como definidos no presente relatório, métodos de preparação dos ditos compostos, compostos intermediários úteis para preparação dos ditos compostos, composições e combinações farmacêuticas compreendendo os ditos compostos e ao uso dos ditos compostos para fabricação de composições farmacêuticas para o tratamento ou profilaxia de doenças, em particular de distúrbios hiperproliferativos, especialmente doenças associadas a sos1, como um agente único ou em combinação com outros ingredientes ativos.
BR112023019030A 2021-04-14 2022-04-13 Derivados de fósforo como inibidores de sos1 BR112023019030A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21168256.2A EP4074317A1 (en) 2021-04-14 2021-04-14 Phosphorus derivatives as novel sos1 inhibitors
PCT/EP2022/059857 WO2022219035A1 (en) 2021-04-14 2022-04-13 Phosphorus derivatives as novel sos1 inhibitors

Publications (1)

Publication Number Publication Date
BR112023019030A2 true BR112023019030A2 (pt) 2023-10-24

Family

ID=75529812

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019030A BR112023019030A2 (pt) 2021-04-14 2022-04-13 Derivados de fósforo como inibidores de sos1

Country Status (18)

Country Link
EP (2) EP4074317A1 (pt)
JP (1) JP2024513595A (pt)
KR (1) KR20230170032A (pt)
CN (1) CN117500507A (pt)
AR (1) AR125672A1 (pt)
AU (1) AU2022258751A1 (pt)
BR (1) BR112023019030A2 (pt)
CA (1) CA3216503A1 (pt)
CL (1) CL2023003045A1 (pt)
CO (1) CO2023013469A2 (pt)
CR (1) CR20230485A (pt)
DO (1) DOP2023000218A (pt)
EC (1) ECSP23077322A (pt)
IL (1) IL307448A (pt)
MX (1) MX2023012187A (pt)
PE (1) PE20240022A1 (pt)
TW (1) TW202304467A (pt)
WO (1) WO2022219035A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230095878A (ko) * 2020-05-09 2023-06-29 치아타이 티안큉 파마수티컬 그룹 주식회사 인을 함유하는 sos1 억제제
WO2023134374A1 (zh) * 2022-01-12 2023-07-20 如东凌达生物医药科技有限公司 一类嘧啶并杂环类化合物、制备方法和用途
WO2024056782A1 (en) * 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2015A (en) 1841-03-26 Improvement in rotary steam-engines
IL89027A (en) 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
GT198900008A (es) 1988-01-29 1990-07-17 Derivados de quinolina, quinazolina y cinolina.
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5236925A (en) 1991-10-24 1993-08-17 American Home Products Corporation Fused pyrimidines as angiotensin II antagonists
ATE345330T1 (de) 1997-08-25 2006-12-15 Bayer Corp Heterozyclische ketonen als npy y5 antagonisten
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003299943A1 (en) * 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2005005382A2 (en) 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods
US7452893B2 (en) 2003-08-15 2008-11-18 Merck & Co., Inc. 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists
ZA200609259B (en) 2004-04-30 2008-07-30 Takeda Pharmaceutical Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
SE0401540D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
ITMI20042042A1 (it) 2004-10-26 2005-01-26 Pharmeste Srl Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
US7572801B2 (en) 2006-05-23 2009-08-11 Hoffmann-La Roche Inc. Pyridopyrimidinone derivatives which are HM74A agonists
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
AU2009276339B2 (en) 2008-07-31 2012-06-07 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
MY152008A (en) 2008-08-27 2014-08-15 Takeda Pharmaceutical Pyrrole compounds
CN105837560A (zh) 2009-02-27 2016-08-10 埃姆比特生物科学公司 调控jak激酶的喹唑啉衍生物和其使用方法
US8461164B2 (en) 2009-08-31 2013-06-11 Dow Agrosciences, Llc. Pteridines and their use as agrochemicals
WO2011028741A1 (en) 2009-09-03 2011-03-10 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
MX2013002384A (es) 2010-09-01 2013-07-05 Ambit Biosciences Corp Compuestos quinazolina y metodos para utilizarlos.
PL2611300T3 (pl) 2010-09-03 2016-10-31 Podstawione skondensowane pochodne dihydropirymidynonów
CA2815131C (en) 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators
WO2012066122A1 (en) 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CN102584828B (zh) 2011-01-14 2016-01-27 上海艾力斯医药科技有限公司 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN102911172A (zh) 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
JP6096778B2 (ja) 2011-09-01 2017-03-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピロロピラジンキナーゼ阻害剤
CN103387490B (zh) 2012-05-09 2015-08-26 中国科学院兰州化学物理研究所 一种甲苯羰化合成苯乙酸的方法
ES2624223T3 (es) 2012-06-08 2017-07-13 Gilead Sciences, Inc. Inhibidores macrocíclicos de los virus flaviviridae
EP2938608B1 (en) 2012-12-20 2021-08-04 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
CA2894642A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014153666A1 (en) 2013-03-29 2014-10-02 Vida Therapeutics, Inc. Indoline compounds as granzyme b inhibitors
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
AU2014296184B2 (en) 2013-07-31 2017-04-27 Gilead Sciences, Inc. Syk inhibitors
WO2015155306A1 (en) 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
CN106715435B (zh) 2014-09-15 2019-10-01 卢郡控股(开曼)有限公司 作为nr2b nmda受体拮抗剂的吡咯并嘧啶衍生物
US9643965B2 (en) 2014-09-17 2017-05-09 Celgene Quantical Research, Inc. Histone demethylase inhibitors
WO2016049048A1 (en) 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
CN104803954B (zh) 2015-04-30 2018-01-26 上海应用技术学院 一种福沙那韦中间体的制备方法
AU2016290987C1 (en) 2015-07-08 2023-07-20 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10793582B2 (en) 2015-10-22 2020-10-06 Mitsubishi Tanabe Pharma Corporation Bicyclic heterocyclic compound
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
EP3878850A1 (en) 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
EP3601267A1 (en) 2017-03-21 2020-02-05 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
FR3066761B1 (fr) 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
CR20210307A (es) 2017-12-21 2021-07-27 Boehringer Ingelheim Int NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312)
EA202092094A1 (ru) 2018-03-05 2020-12-10 Бристол-Маерс Сквибб Компани Фенилпирролидиноновые агонисты формилпептидного рецептора 2
CN109776607B (zh) 2019-02-21 2021-06-04 青岛海洋生物医药研究院 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3931195A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
KR20230095878A (ko) 2020-05-09 2023-06-29 치아타이 티안큉 파마수티컬 그룹 주식회사 인을 함유하는 sos1 억제제

Also Published As

Publication number Publication date
MX2023012187A (es) 2023-10-25
CO2023013469A2 (es) 2024-04-29
EP4322962A1 (en) 2024-02-21
EP4074317A1 (en) 2022-10-19
PE20240022A1 (es) 2024-01-04
ECSP23077322A (es) 2023-11-30
CL2023003045A1 (es) 2024-03-22
AR125672A1 (es) 2023-08-02
AU2022258751A1 (en) 2023-10-05
KR20230170032A (ko) 2023-12-18
DOP2023000218A (es) 2023-11-15
CR20230485A (es) 2023-12-12
CA3216503A1 (en) 2022-10-20
IL307448A (en) 2023-12-01
TW202304467A (zh) 2023-02-01
CN117500507A (zh) 2024-02-02
WO2022219035A1 (en) 2022-10-20
JP2024513595A (ja) 2024-03-26

Similar Documents

Publication Publication Date Title
BR112023019030A2 (pt) Derivados de fósforo como inibidores de sos1
BR112019009529A2 (pt) novos derivados de quinolina
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
BR112022020841A2 (pt) Inibidores de kras tricíclicos fundidos
CO2018010966A2 (es) Nuevos derivados de pirazolopirimidina
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
BR112022019057A2 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
ECSP034916A (es) Oxazolidinonas substituidas para terapia de combinacion
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BR112013011634A2 (pt) derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c]
SV2010003706A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
BR112022023271A2 (pt) Compostos
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
PH12020500134A1 (en) Dihydrooxadiazinones
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
BR112022001628A2 (pt) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
BR112021020241A2 (pt) Derivados de heteroarila bicíclica como inibidores de ectonucleotídeo pirofosfatase fosfodiesterase 1
BR112022023983A2 (pt) Compostos terapêuticos
BR112018074381A2 (pt) [8-(fenil sulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il] (1h-1,2,3-triazol-4-il)metanonas
BR112022020315A2 (pt) Novos compostos anti-helmínticos
BR112022001390A2 (pt) Inibidores de enzima